Beyond KRAS mutation status: influence of KRAScopy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

被引：0
|
作者：
Leonie JM Mekenkamp
Jolien Tol
Jeroen R Dijkstra
Inge de Krijger
M Elisa Vink-Börger
Shannon van Vliet
Steven Teerenstra
Eveline Kamping
Eugène Verwiel
Miriam Koopman
Gerrit A Meijer
J Han JM van Krieken
Roland Kuiper
Cornelis JA Punt
Iris D Nagtegaal
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Medical Oncology
[2] Radboud University Nijmegen Medical Centre,Department of Pathology
[3] Radboud University Nijmegen Medical Centre,Department of Epidemiology, Biostatistics and Health Technology Assessment
[4] Radboud University Nijmegen Medical Centre,Department of Human Genetics
[5] University Medical Center Utrecht,Department of Medical Oncology
[6] VU University Medical Center,Department of Pathology
[7] University of Amsterdam,Department of Medical Oncology, Academic Medical Centre
来源：
BMC Cancer | / 12卷
关键词：
Cetuximab; KRAS Mutation; Copy Number Change; Poor Responder; Copy Number Gain;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer
    Yarom, Nirit
    Gresham, Gillian
    Boame, Nana
    Jonker, Derek
    CLINICAL COLORECTAL CANCER, 2019, 18 (04) : E309 - E315
  • [32] KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
    Hebbar, M.
    Fournier, P.
    Romano, O.
    EUROPEAN JOURNAL OF CANCER CARE, 2010, 19 (02) : 167 - 171
  • [33] Effect of KRAS mutational status on disease behavior and treatment outcome in patients with metastatic colorectal cancer: intratumor heterogeneity and mutational status
    Rasmy, Ayman
    Fayed, Alaa
    Omar, Ayman
    Fahmy, Nermin
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (05) : 886 - 895
  • [34] Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy
    Jensen, B. V.
    Schou, J. V.
    Johannesen, H. H.
    Christensen, I. J.
    Nielsen, D.
    Johansen, J. S.
    Hogdall, E. V.
    Larsen, O.
    Yilmaz, M.
    Pfeiffer, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] MicroRNA profile and KRAS status in metastatic colorectal cancer
    Valladares-Ayerbes, M.
    Blanco, M.
    Reboredo, M.
    Lorenzo-Patino, M. J.
    Arnal, F.
    Conde, M. Haz
    Medina Villaamil, V.
    Santamarina Cainzos, I.
    Anton Aparicio, L. M.
    Calvo Martinez, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [36] The Importance of KRAS Status in Managing Metastatic Colorectal Cancer
    Leong, Stephen
    Eckhardt, S. Gail
    Jimeno, Antonio
    Messersmith, Wells
    CURRENT COLORECTAL CANCER REPORTS, 2009, 5 (03) : 129 - 134
  • [37] Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer
    Perkins, Geraldine
    Pilati, Camilla
    Blons, Helene
    Laurent-Puig, Pierre
    PHARMACOGENOMICS, 2014, 15 (07) : 1043 - 1052
  • [38] Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan
    Alkader, Mohammad S.
    Altaha, Rashed Z.
    Badwan, Sinan A.
    Halalmeh, Anees I.
    Al-Khawaldeh, Muna H.
    Atmeh, Mousa T.
    Jabali, Eslam H.
    Attieh, Ola
    Al-Soudi, Hana S.
    Alkhatib, Lean A.
    Alrawashdeh, Mohammad T.
    Abdelqader, Aseel F.
    Ashokaibi, Omar Y.
    Shahin, Ahmed A.
    Maaita, Fadi M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
  • [39] CORRELATION OF BRAF STATUS WITH CLINICAL RESPONSE TO CETUXIMAB IN KRAS WILD TYPE (KRAS WT) METASTATIC COLORECTAL (MCRC) PATIENTS - SINGLE INSTITUTION EXPERIENCE
    Rebersek, M.
    Ocvirk, J.
    Boc, M.
    Cerkovnik, P.
    Novakovic, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
  • [40] Clinical benefits of bevacizumab in metastatic colorectal cancer depending on KRAS status.
    Kurimoto, Keisuke
    Ishigure, Kiyoshi
    Kato, Yoshiyasu
    Asai, Yasuyuki
    Tanaka, Nobutake
    Ryo, Song
    Matsushita, Hidenobu
    Tobinaga, Junichi
    Fukuyama, Ryuichi
    Kuroda, Hiruhumi
    Fujii, Tomoo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345